● Recruiting

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

Condition: Diffuse Large B-Cell Lymphoma (DLBCL) · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

PhasePhase 2

Planned participants48

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

hui Liu · +86 13819198629 · sylen@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07078500